I had hoped that this report would clear up the inconsistency of the data in the Tandem Meetings abstract, where the copy relating to Cohort B - who were treated with azer-cel, lymphodepletion (chemotherapy), and interleukin-2 (IL-2) - reports 3 complete responses, whereas the table reports only 2.
Instead, the pertinent words in this quarterly are “The trial has already shown promising initial results at US sites, with three complete responses reported, including two from patients in Cohort B.”
Imugene’s language regarding trial responses in its announcements up to now has been “achieved”.(e.g. “3 complete responses achieved”).
I’m not interested in reading again what’s been reported - I know that information - I’d like to know what’s been achieved.
Frustratingly, it seems we’re going to have to wait until the conference itself to see what the story really is.
IMU Price at posting:
3.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)